Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Imrich, Markuljak"'
Autor:
Hana Klamová, Kateřina Machová Poláková, Jan Mužík, Zdeněk Ráčil, Daniela Žáčková, Kateřina Steinerová, Michal Karas, Edgar Faber, Eva Demečková, Zuzana Michalovičová‐Sninská, Jaroslava Voglová, Ľudmila Demitrovičová, Eva Mikušková, Elena Tóthová, Juraj Chudej, Imrich Markuljak, Eduard Cmunt, Jana Moravcová, Dana Dvořáková, Kyra Michalová, Marie Jarošová, Markéta Marková Šťastná, Petr Cetkovský, Ladislav DuŠek, Vladimír Koza, Marek Trněný, Karel Indrák
Publikováno v:
Cancer Medicine, Vol 2, Iss 2, Pp 216-225 (2013)
Abstract We evaluated responses to the treatment and long‐term outcomes of chronic myeloid leukemia patients treated with imatinib as first‐line treatment in routine clinical setting from two countries with centralized tyrosine kinase inhibitors
Externí odkaz:
https://doaj.org/article/3352c3f69ea544aab068556ac3c96068
Autor:
Imrich Markuljak, Ivan Spicka, Leah Fink, Daniel Coriu, Georgi Mihaylov, Katja Björklöf, Slobodanka Ostojic-Kolonic, Krisztian S Toka, Dominik Dytfeld, Daniela Niepel
Publikováno v:
Polish Archives of Internal Medicine.
Introduction Multiple myeloma (MM) treatment has evolved substantially in recent years. Solid data on the impact of treatment strategies on patient outcomes beyond clinical trials are scarce, especially in budget‑restricted environments with limite
Autor:
Daniela Zackova, Jaroslava Voglová, Katerina Machova Polakova, Karel Indrak, Jiri Mayer, Edgar Faber, Ludmila Demitrovicova, Jan Muzik, Imrich Markuljak, Juraj Chudej, Eduard Cmunt, Ladislav Dušek, Hana Klamova, Elena Tóthová, Zdenek Racil, Michal Karas, Tomas Kozak, Marie Jarošová, Eva Janoušová, Tomáš Pavlík, Eva Demečková
Publikováno v:
American Journal of Hematology. 88:790-797
Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as well as the level of BCR-ABL1 and the achievement of complete cytogenetic response (CCgR) at
Autor:
Marek Trněný, Michal Karas, Imrich Markuljak, Kateřina Machová Poláková, Jaroslava Voglová, Karel Indrak, Jan Mužík, Kyra Michalova, Marie Jarošová, Markéta Marková Šťastná, Vladimir Koza, Zdeněk Ráčil, Kateřina Steinerová, Elena Tóthová, Ľudmila Demitrovičová, Eva Mikuskova, Eva Demečková, Eduard Cmunt, Edgar Faber, Daniela Žáčková, Ladislav Dušek, Dana Dvořáková, Zuzana Michalovičová-Sninská, Hana Klamova, Juraj Chudej, Petr Cetkovský, Jana Moravcová
Publikováno v:
Cancer Medicine. 2:216-225
We evaluated responses to the treatment and long-term outcomes of chronic myeloid leukemia patients treated with imatinib as first-line treatment in routine clinical setting from two countries with centralized tyrosine kinase inhibitors (TKIs) treatm
Autor:
Eduard Cmunt, Ludmila Demitrovicova, Jaroslava Voglová, Imrich Markuljak, Juraj Chudej, Tomas Kozak, Edgar Faber, Marie Jarošová, Karel Indrak, Vladimir Koza, Elena Tóthová, Ladislav Dušek, Eva Demečková, Jan Mužík
Publikováno v:
European Journal of Haematology. 87:157-168
Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres duri
Autor:
Ludmila Demitrovicova, Jana Lesko-Andrascikova, Adriana Kafková, Zuzana Sninská, Eva Mikuskova, Martin Mistrik, Tereza Nečasová, Stanislav Palasthy, Katarina Slezakova, Juraj Chudej, Eva Koritakova, Imrich Markuljak, Natalia Stecova, Elena Tóthová
Publikováno v:
ResearcherID
Introduction: With the onset of tyrosine kinase inhibitors (TKI) to treat patients with CML, the number of patients and overall survival increased and quality of life significantly improved. The basic principle of therapy was also changed, according
Autor:
Hana, Klamová, Kateřina Machová, Poláková, Jan, Mužík, Zdeněk, Ráčil, Daniela, Záčková, Kateřina, Steinerová, Michal, Karas, Edgar, Faber, Eva, Demečková, Zuzana, Michalovičová-Sninská, Jaroslava, Voglová, Ludmila, Demitrovičová, Eva, Mikušková, Elena, Tóthová, Juraj, Chudej, Imrich, Markuljak, Eduard, Cmunt, Jana, Moravcová, Dana, Dvořáková, Kyra, Michalová, Marie, Jarošová, Markéta Marková, Sťastná, Petr, Cetkovský, Ladislav, Dušek, Vladimír, Koza, Marek, Trněný, Karel, Indrák
Publikováno v:
Cancer Medicine
We evaluated responses to the treatment and long-term outcomes of chronic myeloid leukemia patients treated with imatinib as first-line treatment in routine clinical setting from two countries with centralized tyrosine kinase inhibitors (TKIs) treatm
Autor:
Edgar, Faber, Jan, Mužík, Vladimír, Koza, Eva, Demečková, Jaroslava, Voglová, Ludmila, Demitrovičová, Juraj, Chudej, Imrich, Markuljak, Eduard, Cmunt, Tomáš, Kozák, Elena, Tóthová, Marie, Jarošová, Ladislav, Dušek, Karel, Indrák
Publikováno v:
European journal of haematology. 87(2)
Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres duri
Autor:
Martin Mistrik, Katarina Richterova, Petr Brabec, Elena Tóthová, Stanislav Palasthy, Imrich Markuljak, L'ubica Valekova
Publikováno v:
Blood. 118:5051-5051
Abstract 5051 While clinical studies and guidelines provide important data regarding the safety and efficacy of new drugs, their application to daily practice can be limited by the inclusion of selected patient populations. Population-based studies c
Autor:
Eduard Cmunt, Katerina Machova-Polakova, Katerina Steinerova, Edgar Faber, Marek Trneny, Jaroslava Voglová, Jiri Mayer, Daniela Zackova, Imrich Markuljak, Ladislav Dušek, Martin Mistrik, Karel Indrak, Hana Klamova, Juraj Chudej, Jan Muzik, Eva Demečková, Elena Tóthová, Michal Karas, Kyra Michalova, Ludmila Demitrovicova, Tomas Kozak, Marie Jarošová
Publikováno v:
ResearcherID
Abstract 1239 Background. Imatinib (IM), a selective BCR-ABL tyrosine kinase inhibitor (TKI), is a treatment of choice for newly diagnosed chronic myeloid leukemia (CML) patients (pts) in chronic phase (CP) as it was shown in the IRIS trial. The trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02d6343a2167f148427b4bd1a35a633a
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000289662201342&KeyUID=WOS:000289662201342
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000289662201342&KeyUID=WOS:000289662201342